Avila RH, Sandoval-Zamora H, Pérez-Neri I

Language: Spanish
References: 9
Page: 70-72
PDF size: 95.41 Kb.

Text Extraction

No abstract.

REFERENCES

1. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol (Oxford) 2015;29(2):97-115.

2. Lorenz RC, Gleich T, Buchert R, Schlagenhauf F, Kühn S, Gallinat J. Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum. Hum Brain Mapp 2015;36(10):4031-40.

3. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatr 1999;46(10):1388-95.

4. Smith Y. Glutamatergic Pathways: their relevance for psychiatric diseases. In: Schmidt WJ, Reith MEA, editors. Dopamine and glutamate in psychiatric disorders. Totowa, N.J.: Humana Press 2005 pp. 65 -77.

5. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatr 2000;48(7):627-40.

6. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20(3):201-25.

7. Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 2007;78:69-108.

8. Meltzer LT, Christoffersen CL, Serpa KA. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev 1997;21(4):511-8.

9. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 2003;1003:138-58.